Secretary General of the Moroccan Ministry of Health made report at the "Biology and Life Science Technology and Industry Branch of the Conference" in China.

 The School of Medicine and its affiliated Ruijin Hospital hosted the "International Conference on Innovation and Emerging Industry Development" Biology and Life Science Technology and Industry Branch

Release date: 2018-09-21 00:00:00    

　　From September 19th to 20th, led by the Chinese Academy of Engineering, the Shanghai Municipal People's Government, the Ministry of Industry and Information Technology, together with the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Commerce, the Chinese Academy of Sciences, the China Council for the Promotion of International Trade, the United Nations Industrial Development The organization and other departments jointly held a grand event with the theme of "Technology Innovation Leading the Development of Emerging Industries" at the Shanghai International Convention Center. The Biology and Life Science Technology and Industry Branch organized by Shanghai Jiaotong University School of Medicine and Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine was held on September 20. The branch mainly focuses on the development of international frontier biomedical science and technology and industry, focusing on the enhancement of biotechnology integration innovation capabilities and achievements transformation capabilities. Fan Xianqun, Deputy Secretary of the Party Committee of Shanghai Jiao Tong University and Secretary of the Party Committee of the School of Medicine, delivered a speech. Zhang Xiping, Inspector of the Shanghai Economic and Information Work Party Committee and Member of the Party Committee, gave a welcome speech. Academician of the Chinese Academy of Engineering, Director of the Shanghai Institute of Endocrinology and Metabolism, Shanghai Ning Guang, Vice President of Ruijin Hospital Affiliated to Jiaotong University School of Medicine, delivered a closing speech. Hao Xishan, academician of the Chinese Academy of Engineering, director of the Tianjin Cancer Institute, and director of the National Cancer Center for Clinical Medicine, and Tan Tianwei, an academician of the Chinese Academy of Engineering and president of Beijing University of Chemical Technology, chaired the morning and afternoon sessions respectively.

　　In his speech, Fan Xianqun first expressed his warm welcome and heartfelt thanks to leaders, guests, experts and scholars from all over the world on behalf of Shanghai Jiaotong University School of Medicine. He pointed out that the development and progress of medicine need innovation as the soul, and always adhere to humanistic care, put the interests and needs of patients first, and solve the health problems that people are most concerned about. Shanghai Jiaotong University School of Medicine and its affiliated Ruijin Hospital have been promoting innovation and development with a tenacious spirit, boosting the development of China's medical and health services and the improvement of national health, and have formed many practical concepts and experiences. It is hoped that Through the convening of this conference, we will continue to strengthen international exchanges in the field of health care, share experience and achievements, build a platform and bridge for cooperation, and jointly make more contributions to the cause of human health.

　　At the meeting, Professor Hicham Nejmi, Secretary General of the Ministry of Health of the Kingdom of Morocco, Gu Xiaosong, Academician of the Chinese Academy of Engineering, Katrin Rupalla, Global R&D Director of Oncology Drugs, Bristol-Myers Squibb Pharmaceuticals, USA, Takahide Tanaka, Executive Director of Japan Omron Health Care Co., Ltd., President of the Swiss National Academy of Medicine, Switzerland Daniel Scheidegger, Professor of the Department of Anesthesiology, University of Basel, Pirjo Nuutila, Academician of the National Academy of Sciences of Finland, Professor of Metabolic Diseases at the University of Turku, Yin Yuxin, Director of the Institute of Systems Biomedicine, Peking University, and 14 scholars, experts and well-known enterprises from 9 countries Jia shared reports, focusing on new methods and research concepts in biotechnology, medical applications of big data and artificial intelligence, cellular and cancer immunity, genomic and molecular biology, medical and pharmaceutical biotechnology, enzyme and protein engineering, biological Informatics and systems biology, biomedical engineering technology and other topics are aimed at promoting the exchange of theoretical applications and technological development in this field.

　　Precision medicine is a hot topic in the current focus. From treatment to prevention, the ultimate goal of precise diagnosis and precision medicine should be precise health. Takahide Tanaka, executive executive director of Japan's Omron Health and Medical Co., Ltd., shared a case of shifting from disease treatment to preventive medicine. "In 1973, when we sold the first blood pressure monitor, doctors even accused us, but now measuring blood pressure at home has become the norm, and the sales have reached 200 million." He believes that behind this is the change in residents' medical concept and self-esteem. Increased health concerns. Pirjo Nuutila, a member of the Finnish National Academy of Sciences and a professor of metabolic disease at the University of Turku in Finland, said the Finnish government had been working on the establishment of "My Database" 10 years ago. This database includes three levels. The first level is the personal genome, which is mainly used to observe genetic information, because genes play a 40% role in determining each person's physical condition; the second level is electronic medical records, which are derived from Information collected by hospitals and pharmacies; the third layer is personal health data, including people's usual exercise and diet. What we're doing now is working on using the information in the database for healthcare.

　　The significance of precision medicine is not limited to doctors and patients. For biopharmaceutical companies, precision medicine also points out a direction for them. For example, Katrin Rupalla, global research and development director of oncology drugs at Bristol-Myers Squibb Pharmaceuticals, "The disease spectrum in different regions shows differences between populations in different regions." For example, the incidence of nasopharyngeal cancer in southern China is higher than that in the north, so pharmaceutical companies can adapt to different regions. Research and development of different types of drugs. "Different regions have different combinations of disease bands, which can not only reflect the combination of diseases that endanger people in a certain place, but also guide relevant units to carry out targeted work."

　　Experts and scholars at the meeting also held lively seminars and questions and answers. This biological and life science technology and industry branch attracted more than 200 researchers from all over the country to participate, and the venue was full.